Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men
Authors:
- Andrzej SzczeklikASAndrzej Szczeklik
- Ryszard J. GryglewskiRGRyszard J. Gryglewski
- Rafał NizankowskiRNRafał Nizankowski
- Jacek MusiałJMJacek Musiał
- Ryszard PietońRPRyszard Pietoń
- Józef MrukJMJózef Mruk
- 1 June 1978
- journal article
- research article
- Published by Elsevier in Pharmacological Research Communications
- Vol. 10 (6) , 545-556
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- In vivo method for quantitation of anti-platelet potency of drugsNaunyn-Schmiedeberg's Archives of Pharmacology, 1978
- Sulfinpyrazone in the Prevention of Cardiac Death after Myocardial InfarctionNew England Journal of Medicine, 1978
- The generation of prostacyclin by arteries and by the coronary vascular bed is reduced in experimental atherosclerosis in rabbitsProstaglandins, 1977
- PLATELET ACTIVATION IN ACUTE CEREBRAL ISCHÆMIAThe Lancet, 1977
- Modulation of human platelet adenylate cyclase by prostacyclin (PGX)Prostaglandins, 1977
- Prostacyclin (PGX) is the endogeneous metabolite responsible for relaxation of coronary arteries induced by arachidonic acidProstaglandins, 1977
- Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxidesProstaglandins, 1976
- An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregationNature, 1976
- Aspirin as an Antiplatelet Agent: Template Bleeding Time as a Monitor of TherapyAmerican Journal of Clinical Pathology, 1973